Srikanth Muppidi, MD
Clinical Neurophysiology · Stanford, CANPI 1568641736
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $121,908 of the $149,748 with a category attached, or 81.4%. 16 manufacturers reported payments, led by AstraZeneca at 29.7% of the total. Among clinical neurophysiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 136 payments — averaging $1101.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$44K
- UCB SA$27K
- Amgen$24K
- Argenx US, Inc.$18K
- UCB, Inc.$13K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- plus $13K from 10 others
Across 51 payments — averaging $12,356 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$339K
- AstraZeneca$290K
- Novartis Pharma AG$1K
What the payments were for
- Consulting fees$121,90881%
- Speaking & faculty fees$7,9155%
- Travel & lodging$16,47311%
- Food & beverage$3,4512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 52 | $44,455 |
| UCB SA | 6 | $27,489 |
| Amgen(2 entities) | 19 | $23,920 |
| Argenx US, Inc. | 27 | $18,379 |
| UCB, Inc. | 9 | $12,600 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $9,464 |
| Johnson & Johnson | 1 | $3,815 |
| Merck Kgaa | 2 | $2,813 |
| Catalyst Pharmaceuticals, Inc. | 3 | $2,525 |
| CSL Behring | 1 | $1,645 |
| Janssen Global Services, LLC | 1 | $1,110 |
| Janssen Scientific Affairs, LLC | 1 | $1,090 |
| Sobi, Inc | 1 | $150 |
| Alnylam Pharmaceuticals Inc. | 1 | $138 |
| Novartis | 1 | $131 |
| Biogen | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$149,748 in reported general payments places this provider in the 95th percentile of 49 clinical neurophysiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvgartEfgartigimod Alfa-Fcab | 28 | $1,295,914 |
| ZilbrysqZilucoplan Sodium | 21 | $754,804 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 67 | $699,730 |
| Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc | 26 | $559,073 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 45 | $428,014 |
| BivigamImmun Glob G(Igg)/Gly/Iga Ov50 | 18 | $337,863 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 35 | $250,509 |
| Mycophenolic AcidMycophenolate Sodium | 31 | $29,313 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 24 | $13,238 |
| RasuvoMethotrexate/Pf | 23 | $12,813 |
| Mycophenolate Mofetil | 74 | $11,028 |
| Pyridostigmine Bromide | 115 | $10,394 |
| Droxidopa | 18 | $6,855 |
| Azathioprine | 56 | $6,043 |
| TrexallMethotrexate Sodium | 14 | $4,926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Argenx US, Inc.Vyvgart, Vyvgart Hytrulo | $18,379 | $1,854,98754 claims |
| UCB, Inc.Zilbrysq | $12,600 | $754,80421 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $9,464 | $699,73067 claims |
| CSL BehringPrivigen | $1,645 | $250,50935 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 clinical neurophysiology providers in California.
Other clinical neurophysiology in Stanford
- Christopher LockStanford$159K
- Mitchell MiglisStanford$51K
- Safwan JaradehStanford$34K
- Margaret FerrisStanford$18K
- Kathleen PostonStanford$18K
- Helen Bronte-StewartStanford$7K
- Jaime LopezStanford$1K
- Sungho ChoStanford$1K
- Felix ChangStanford$974
- Laurice YangStanford$924
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.